Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis
暂无分享,去创建一个
[1] C. Spivey,et al. A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States , 2018, Rheumatology and Therapy.
[2] J. O'dell,et al. It is the Best of Treatments, It is the Worst of Treatments: The Continuing Love‐Hate Relationship With Glucocorticoids in Rheumatoid Arthritis , 2017, Arthritis care & research.
[3] R. Desai,et al. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis , 2017, Arthritis Research & Therapy.
[4] H. Sayles,et al. Utilization of Care Outside the Veterans Affairs Health Care System by US Veterans With Rheumatoid Arthritis , 2017, Arthritis care & research.
[5] T. Mikuls,et al. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis , 2017, Arthritis care & research.
[6] R. Sruamsiri,et al. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents , 2017, Current medical research and opinion.
[7] K. Michaud,et al. Changes in Body Mass Related to the Initiation of Disease‐Modifying Therapies in Rheumatoid Arthritis , 2016, Arthritis & rheumatology.
[8] Charles King,et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.
[9] K. Roback,et al. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register‐Based Study of 4,010 Patients in Sweden , 2015, Arthritis care & research.
[10] M. Dougados,et al. Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study , 2015, The Journal of Rheumatology.
[11] R. Hansen,et al. Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis , 2014, Journal of managed care & specialty pharmacy.
[12] K. Rascati,et al. Factors Associated With The Initiation Of Biologic Disease Modifying Antirheumatic Drugs In Texas Medicaid Patients With Rheumatoid Arthritis , 2014 .
[13] Z. Mulla,et al. Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study , 2013, BMJ Open.
[14] R. Caporali,et al. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. , 2013, Clinical and experimental rheumatology.
[15] B. Ng,et al. Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis , 2013, Clinical Rheumatology.
[16] A. Reimold,et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice , 2011, Arthritis care & research.
[17] W. Dixon,et al. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses , 2011, Arthritis research & therapy.
[18] Sebastian Schneeweiss,et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.
[19] Jeffrey N Katz,et al. Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.
[20] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.
[21] John Wong,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.
[22] D. Solomon,et al. Physician preference motivates the use of anti–tumor necrosis factor therapy independent of clinical disease activity , 2010, Arthritis care & research.
[23] K. Anstrom,et al. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. , 2009, Clinical therapeutics.
[24] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[25] B. Gage,et al. Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.
[26] T. Mikuls,et al. Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[27] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .
[28] J. Listing,et al. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. , 2013, Rheumatology.
[29] Mary K Goldstein,et al. Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. , 2002, The American journal of managed care.